Important Class Action Notice for Allarity Investors
Attention investors of Allarity Therapeutics, Inc. (NASDAQ: ALLR): it is crucial to be informed about the ongoing class action lawsuit concerning the company's securities. This action revolves around events that unfolded between May 17, 2022, and July 19, 2024. An important deadline is fast approaching, and you may be entitled to compensation if you purchased securities during this period.
Why This Notice is Important
The Rosen Law Firm is reaching out to remind all investors about the November 12, 2024, lead plaintiff deadline. If you fall under the umbrella of investors who bought securities during the class period, you have a significant stake in this matter. The experienced legal team at Rosen Law Firm emphasizes the opportunity for affected investors to potentially recover losses incurred without upfront costs. This is through a contingency fee model which means you can pursue your claim without the burden of initial fees.
How to Participate in the Class Action
To join the action, you can simply visit the refund portal that has been established for this case or contact the legal team directly by phone or email for additional information. It is advisable to act promptly if you wish to serve as a lead plaintiff, as timing is of the essence.
Understanding the Class Action Lawsuit
This class action lawsuit has already been initiated in response to serious allegations against Allarity. The complaint claims that during the class period, the company made false and misleading statements regarding its drug candidate, Dovitinib, which aims at treating renal cell carcinoma. Misleading investors about the regulatory prospects of Dovitinib could have significant repercussions, both legally and financially.
Misrepresentation of Dovitinib's Regulatory Status
According to the lawsuit, it is alleged that Allarity overstated the potential approval of the Dovitinib New Drug Application (NDA) and failed to disclose improper conduct concerning this application. The concerns include a lack of compliance with regulatory standards, leading to heightened scrutiny from authorities that could affect the company's future operations and financial standing.
The Importance of Choosing the Right Legal Counsel
Investors are encouraged to choose a law firm that has a proven track record in handling securities class actions. The Rosen Law Firm stands out because of its focus on investor protection and its history of successfully managing similar cases. By selecting qualified counsel, you're ensuring that your rights are represented effectively in this legal battle.
Rosen Law Firm's Achievements
The firm has achieved remarkable results in previous securities cases, including record settlements and recognition in the legal field. In 2019, the firm secured over $438 million for investors, illustrating the commitment to protecting shareholder interests. Furthermore, the firm consistently ranks among the top in terms of the number of class action settlements.
Next Steps for Investors
As an investor, you have a choice. You can enlist the Rosen Law Firm to represent you in this class action, or you may choose to act independently. However, it’s crucial to understand that until a class is certified, you may not be represented unless you take steps to secure a legal advisor. Whether you decide to actively participate or remain a passive class member, awareness of your rights is vital.
Frequently Asked Questions
What is the class action about?
The class action pertains to misleading statements made by Allarity Therapeutics regarding the regulatory status of its drug candidate, Dovitinib.
What is the deadline for joining the class action?
The deadline to join the class action is November 12, 2024.
Do I need to pay upfront fees to join?
No, investors can join the lawsuit under a contingency fee arrangement, meaning no upfront fees are required.
How can I get more information on the case?
Investors can visit the Rosen Law Firm's website or contact them directly via phone or email for more information.
Can I choose my legal counsel?
Yes, you have the right to select your legal representation; however, it is recommended to choose counsel experienced in securities class actions.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Email: case@rosenlegal.com
Website: www.rosenlegal.com
